New Data Show COVID-19 Vaccine Does Not Raise Stroke Risk
T-cell response to Omicron after an mRNA COVID vaccine booster
MS Patients on Anti-CD20 Therapy May Benefit from COVID Booster
Vaccination and immunotherapies in neuroimmunological diseases | Nature Reviews Neurology
Certain immune-suppressing therapies reduce vaccine response in subset of multiple sclerosis patients | Ohio State Medical Center
Frontiers | Cross-sectional analysis of the humoral response after SARS-CoV-2 vaccination in Sardinian multiple sclerosis patients, a follow-up study
COVID-19, Vaccinations & Multiple Sclerosis - Practical Neurology
Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study - ScienceDirect
The ME Association: Covid Autumn Booster Vaccine Information (2023) - The ME Association
Response of COVID-19 vaccination in multiple sclerosis patients following disease-modifying therapies: A meta-analysis - eBioMedicine
COVID-19 vaccination guidance for persons with Multiple Sclerosis (MS) | Multiple Sclerosis Society of NZMultiple Sclerosis Society of NZ
Breakthrough COVID-19 in Patients With Multiple Sclerosis: Snapshot From One Data Registry – Consult QD
Queen Mary University of London
Multiple Sclerosis Patients Show T-Cell Response to COVID-19 Vaccines
Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies - Anat Achiron, Mathilda Mandel, Sapir Dreyer-Alster, Gil Harari, David Magalashvili, Polina Sonis, Mark Dolev,
MS and COVID-19 Vaccines - Advice & Support | MS Society
COVID-19 booster jabs for people with MS this autumn | MS Society
Vaccines | Free Full-Text | Results on SARS-CoV-2 mRNA Vaccine Booster from an Open-Label Multicenter Study in Ofatumumab-Treated Participants with Relapsing Multiple Sclerosis
SARS-CoV-2 vaccination in patients with multiple sclerosis in Germany and the United Kingdom: Gender-specific results from a longitudinal observational study - The Lancet Regional Health – Europe
Vaccines | Free Full-Text | Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: A Systematic Review on Immune Response and Vaccination Recommendations
Vaccines | Free Full-Text | Immune Response to SARS-CoV-2 mRNA Vaccines in an Open-Label Multicenter Study in Participants with Relapsing Multiple Sclerosis Treated with Ofatumumab
Vaccines | Free Full-Text | Neurological Disorders following COVID-19 Vaccination
Vaccination and multiple sclerosis in the era of the COVID-19 pandemic | Journal of Neurology, Neurosurgery & Psychiatry
